医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Oh Has Succeeded in the Research of LASEK on Reduction of Eye Damage

2016年07月21日 PM05:00
このエントリーをはてなブックマークに追加

Smart Multimedia Gallery

 

SEOUL, South Korea

Dr. Oh Jung Woo of EOS eye center released a surprising study that improves the safety of existing vision correction surgeries.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160721005430/en/

While the vision correction surgery has been operated for over three decades, the safety of refractive surgery is still doubtful.

Risks of LASIK include tearing of corneal flap and suction loss when the fixed part of the eyeball is loosened. LASEK has been an effective alternative for this problem, however, carrying out LASEK surgeries also demands at least 5 days for wound recovery, and is very painful due to damage on the epithelium after the surgery.

Dr. Oh’s six-year effort is especially highlighted in the factor analysis that minimizes the ablation amount. Proven by clinical outcomes, his new study also reduces the period of healing recovery up to two days as the range of damage of the corneal epithelium would be decreased only 40% the original method.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160721005430/en/

CONTACT

EOS eye center
Representative : Goeun Lim
TEL : +82-2-6097-0053
http://www.eoseye.co.kr/en/

同じカテゴリーの記事 

  • Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
  • HighField Biopharmaceuticals’ mRNA-based HFG1 Demonstrates Potential as a Longer Acting GLP-1R Agonist for Diabetic Control and Weight Loss
  • Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
  • Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
  • エスリのテクノロジーをALS治療開発研究所が治験場所検索に採用